Abstract
Memogain® (Gln-1062) is an inactive pro-drug of galantamine, the latter being a plant alkaloid approved for the treatment of mild to moderate Alzheimer’s disease. Memogain has more than 15-fold higher bioavailability in the brain than the same doses of galantamine. In the brain, Memogain is enzymatically cleaved to galantamine, thereby regaining its pharmacological activity as a cholinergic enhancer. In animal models of drug-induced amnesia, Memogain produced several fold larger cognitive improvement than the same doses of galantamine, without exhibiting any significant levels of gastrointestinal side effects that are typical for the unmodified drug and other inhibitors of cholinesterases, such as donepezil and rivastigmin. In the ferret, dramatically reduced emetic and behavioral responses were observed when Memogain was administered instead of galantamine. Based on these and other preclinical data, Memogain may represent an advantageous drug treatment for Alzheimer’s disease, combining much lesser gastrointestinal side effects and considerably higher potency in enhancing cognition, as compared to presently available drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Birks, J., Harvey, R., Olin, J., Schneider, L., et al. (2003–2007). ADAS-cog changes after 6 months of treatment, reviews of available clinical studies on FDA-approved acetylcholinesterase inhibitors. Cochrane Lib.
Bontempi, B., Whelan, K. T., Risbrough, V. B., Lloyd, G. K., & Menzaghi, F. (2003). Cognitive enhancing properties and tolerability of cholinergic agents in mice: A comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand of nicotinic acetylcholine receptors. Neuropsychopharmacology, 28, 1235–1246.
Samochocki, M., Höffle, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics, 305, 1024–1036.
Spowart-Manning, L., & van der Staay, F. J. (2004). The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioral and Brain Sciences, 151, 37–46.
Wilcock, G., et al. (2003). A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging, 20, 777–789.
Acknowledgements
The pharmacodynamic studies using the T-maze alternation task in the mouse were performed at Neurofit S.A.S., 67400 Ilkirch, France. The studies of emetic and behavioral responses in the ferret were performed at Syncrosome, 13288 Marseille, France.
Author information
Authors and Affiliations
Corresponding author
Additional information
Proceedings of the XIII International Symposium on Cholinergic Mechanisms
Rights and permissions
About this article
Cite this article
Maelicke, A., Hoeffle-Maas, A., Ludwig, J. et al. Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy. J Mol Neurosci 40, 135–137 (2010). https://doi.org/10.1007/s12031-009-9269-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-009-9269-5